Health Care • Biotechnology: Pharmaceutical Preparations
$7.44 ▲ +0.32
(+4.49%)
MKT CAP: $399.0M • VOL: 2.27M
52W L $7 52W H $24
AVTX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $59.0K | $441.0K | $1.9M |
| YoY Revenue Growth % | -86.6% | -77.1% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$72.9M | -$68.5M | -$27.4M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$78.3M | -$35.1M | -$31.5M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$51.5M | -$49.1M | -$30.7M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$51.5M | -$49.1M | -$30.7M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $15.9M | $134.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $83.0M | $133.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AVTX.